IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 23,086 shares of the medical research company’s stock after acquiring an additional 81 shares during the quarter. New York Life Investment Management LLC’s holdings in IQVIA were worth $4,537,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $27,000. Avior Wealth Management LLC lifted its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $33,000. Assetmark Inc. lifted its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in IQVIA during the 3rd quarter worth approximately $57,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Up 1.3 %

NYSE IQV opened at $188.89 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm’s fifty day moving average price is $199.13 and its 200 day moving average price is $214.96. The company has a market capitalization of $33.26 billion, a price-to-earnings ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $184.66 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IQV shares. UBS Group reduced their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Truist Financial reiterated a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.